Depression Clinical Trial
Official title:
Effectiveness of a Depression Care Management Initiative in Home Healthcare
Depression in older home healthcare patients occurs very often, is typically not treated appropriately, and leads to poor health outcomes. This study tests an intervention, called "Depression Care for Patients at Home" or the Depression CAREPATH, designed to help home healthcare nurses work with the patients, their family, and their doctors in managing depression treat depression according to clinical guidelines and to manage its treatment over time. Patient outcomes, measured at 3, 6, and 12 months, include guideline-consistent changes in depression treatment and reduction in depressive symptoms.
The goal of this research is to improve depression treatment and outcomes among elderly home
healthcare patients. Homecare nursing is a major source of health care for a large and
growing number of medically ill or injured older adults who are homebound by illness or
disability. Clinically significant depression is twice as prevalent in this patient
population compared to similarly aged primary care patients. Depression can be effectively
treated in older adults, and treatment guidelines have been developed to help physicians
make treatment decisions for their depressed older patients. However, medical home
healthcare patients rarely receive guideline-consistent treatment for depression. This
research tests the effectiveness of an intervention, Depression Care for Patients at Home"
(CAREPATH), on two outcomes: 1. Depression treatment (i.e., initiate treatment or have a
change in treatment that is consistent with guidelines), and 2. Depressive symptoms (i.e.,
reduction in depressive symptoms over time). The CAREPATH protocol was designed in
partnership with home healthcare providers. It includes the major elements of depression
care management models that have proven effective in primary care but restructures these
elements to fit the clinical needs of home healthcare patients and for consistency with home
healthcare practice. The intervention itself is designed to be ecologically sensitive to
maximize the feasibility and generalizability of the program. The CAREPATH Intervention is
being tested within six home healthcare agencies located in Vermont/New Hampshire, New York,
Pennsylvania, Michigan, Florida, and Arkansas. The design includes randomization of ~20
teams of nurses to CAREPATH or usual care. The impact of CAREPATH on depression treatment is
tested with all eligible patients (N~600) using data collected routinely by all agencies as
these are the kinds of data that agencies typically use for quality assurance. Depressive
symptoms outcomes are tested using the Hamilton Depression Rating Scale (HDRS) collected by
researcher staff from (N=300) patients who consent to in-person baseline and telephone
follow-up interviews at 12, 24, and 52 weeks.
Data Plan: H1 Depression Treatment : Patients of CAREPATH home nurses with clinically
significant depressive symptoms will be more likely to receive a "guideline-based step" in
their treatment of depression than patients of nurses providing usual care. This analysis
will be tested using the merged administrative data set. A mixed-effects logistic regression
analyses will compare patients in the intervention and usual care groups on change in
depression treatment received. The primary independent variable (a fixed effect) is group
and the dependent variable is change (from start-of-care to discharge to guideline
consistent treatment received (yes/no). The structure of these data from this cluster
randomized trial involves three level mixed-effects models in which patients are nested
within nurse and nurse within team supervisor. These analyses will be preceded by
mixed-effects models that compare groups on sociodemographic and clinical variables. Those
variables that differ significantly will be included as covariates in the primary analysis
that examines the intervention effect (described above).
H2 Depressive Symptoms: Patients of CAREPATH home nurses with clinically significant
depressive symptoms will have greater reduction in depressive symptomatology (HDRS change
from baseline) by 3, 6 and 12 months of the baseline interview than patients receiving usual
care. This analysis will be tested using data collected from patient research interviews. A
mixed-effects linear regression analyses will compare patients in the intervention and usual
care groups on change in severity of depressive symptoms from baseline. Covariates in the
model will be selected as described in H1.
D9.3 Exploratory Analyses: . S1. Different Outcomes:. Whether the intervention reduces the
risk of poor outcomes as measured by Medicare's "Outcome-Based Quality Indicators" (OBQI)
and targeted adverse events, including: decline in activities of daily living, discharge to
hospital, and/or falls. This analysis will be tested using the merged administrative data
set. Mixed-effects analyses will be conducted on the following OBQI outcomes and adverse
events. Mixed-effects linear regression will be used for the continuous measures (e.g., ADL
decline) whereas mixed-effects logistic regression analyses will be used on binary outcomes
(e.g., fall). The choice of covariates and the structure of the data will conform to that
described for H1. We anticipate that some of these exploratory analyses will be sufficiently
power for statistical tests (e.g., decline in ADL), yet others (e.g., adverse fall events)
will be examined for the direction and magnitude of effects rather than statistical
significance.
S2 Patient Characteristics as Moderators: Whether the effects of the intervention on patient
outcomes and quality of care differ by depression severity, patient location (e.g., rural
vs. urban), race/ethnicity (White, Black, Hispanic, Native American), availability of social
support (caregiver), health status, or cognitive impairment. Separate models will examine
each patient characteristic as a moderator using mixed-effects linear or logistic regression
analyses. The independent variables will include intervention and the respective
hypothesized mediating (from post baseline) or moderating (from baseline) effects (described
below). Initially the main effects will be tested. Then subsequent models will examine the
incremental contribution of the interaction of intervention with each of the hypothesized
moderating effects.
D10 POWER ANALYSIS Power analyses for the primary hypotheses were conducted based on the
following assumptions about sample size: 5 agencies; 4 nurse teams per agency, 5 nurses per
team, and 5 patients subjects per nurse. These assumptions result in a patient sample size
of 500 patients (5*4*5*5). We estimate that the number of patients who consent to research
interviews will be about half of the patients who are eligible based in the agency's
database data (i.e., 60% participation at baseline; 85% of baseline patients eligible for
follow-up). Thus the number of patients in the agency's database that could be included in
analyses using the this source of data will be at least 1,000.
Other assumptions for the power analyses included a two-tailed alpha = 0.05, 12 and 24 week
follow-up assessments for each subject, and an attrition rate of 15%. This rate is based on
our six month follow-up rates as well as our experience with other samples of
community-dwelling frail elders (e.g., home care patients), where we have found that
obtaining the first interview is far more difficult than following older adults overtime
once they have met and talked with us. Because computer algorithms are not readily available
for conducting power analyses for three-level mixed-effects models, power estimates for
testing H1 and H2 are based on simulations described below, that involved 1000 simulation
runs for each combination of specifications.
H1 Depression Treatment: The simulations considered two intraclass correlations reflecting
variations in level 1 (subject-level intraclass correlation within nurse) and level 2
(nurse-level intraclass correlation within team). Statistical power to detect the
hypothesized effects with the anticipated sample size, will exceed >80%.
H2 Depressive Symptoms: Power analyses was conducted based on simulation using Mixed-effects
models for level 1 and level 2 level random intercepts 3-level linear mixed effects
regression model. We hypothesized medium intervention effects (Cohen's d) with a
standardized group mean difference in HDRS change from the baseline: 0.5 and 0.6. (These
correspond to differences in HDRS changes = 3.43, and 4.11 based on an estimated residual
standard deviation = 6.85 of HAM-D changes from the TRIAD study.) The table shows that power
to detect effect size > 0.5 is adequate (>80%).
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |